On April 23, we interpreted 15 articles, focusing on: bile acids, fatty liver disease, vaccines, new crown, psychology, celiac disease, colitis, hypertension, horse, paijin biotechnology, Jinfang Pharmaceutical, Bruker, Yili, Jinyu Medical, Kangrun biotechnology.
The daily newspaper was published by R. AI-assisted creation generation, manual review and proofreading.
Jiang Changtao/Qiao Jie/Pang Yanli/Zheng Minghua/Jia Yanxing Cell: Enterobacteria's new secondary bile acids may improve steatohepatitis
Cell——[64.5]
(1) Changtao Jiang, Academician Qiao Jie and Yanli Pang of Peking University, Minghua Zheng of Wenzhou Medical University and Yanxing Jia of Peking University and their team published important studies that discovered a new type of modification of bile acids by intestinal flora, revealed the key intestinal bacteria and biosynthetic pathways, and analyzed the physiological and pathophysiological effects and biological mechanisms of bile acids from this type of bacterial source;(2) Based on the click chemical enrichment strategy combined with the non-targeted metabolomics method, a secondary bile acid mining system was constructed, and a variety of new bile acids containing acylation and widely existing bile acids such as 3-succinylated (3-susCA) were discovered;(3) The main producer of 3-susCA was found to be Bacteroides monoform, and the 3-susCA synthetase BAS-sus was discovered through the activity-based protein tracking and purification strategy;(4) Clinical cohort analysis showed that 3-susCA was negatively correlated with the process of metabolism-related steatohepatitis (MASH), and combined with mouse and in vitro experiments, it was found that 3-susCA could enhance the amination and utilization of glucose by beneficial Akksa mucchiphila (Akk bacteria) to promote the growth of Akk bacteria, improve intestinal barrier damage, reduce chronic low-grade inflammation, and thus improve MASH;(5) This study provides a new paradigm for mining bacteria-derived bile acids and bacteria-derived enzymes related to host health.
【Original Information】
Gut symbionts alleviate MASH through a secondary bile acid biosynthetic pathway
2024-04-22 , Yogurt: 10.1016/J.Cell.2024.03.034.034
Nature: Improving diet before vaccination enhances immune response in obese mice
Nature Microbiology——[28.3]
(1) Metabolic diseases are epidemially linked to serious complications of influenza virus infection, but the response to vaccines in this high-risk group is poor, and this study found that changing dietary habits before influenza vaccination can improve the immune response and metabolic status of previously obese mice;(2) systemic metabolic inflammation caused by high-fat diet restricts the maturation of T cells to memory cells during vaccination, and affects the recall of effector memory T cells when challenged by the virus;(3) Dietary changes after vaccination did not improve the situation, but if weight loss was achieved 4 weeks prior to vaccination, it could reverse the metabolic dysfunction of T cells and thus restore their functional recall response; (4) This corresponded to changes in the systemic obesity-associated biomarkers leptin and adiponectin, highlighting the systemic and specific effects of diet on the immunogenicity of influenza vaccines.
【Original Information】
Diet switch pre-vaccination improves immune response and metabolic status in formerly obese mice
2024-04-18 , doi: 10.1038/s41564-024-01677-Y
Domestic team: The influence of intestinal microbiota on the infection and pathogenesis of the new coronavirus
Gut Microbes——[12.2]
(1) The team of Hongqi Liu, Shuaiyao Lu and Xiaozhong Peng of the Chinese Academy of Medical Sciences revealed the potential role of gastrointestinal microbiota and its metabolites in the pathogenicity of different SARS-CoV-2 variants in rhesus macaques;(2) Comprehensive histopathology, microbiome and transcriptomics analysis of the gastrointestinal tissues of rhesus monkeys infected by SARS-CoV-2 prototypes and its variants revealed two different virus clusters: Alpha, Beta and Delta (ABD) clusters and Proto and Omicron (PO) clusters;(3) The abundance of potentially pathogenic microorganisms such as UCG-002, UCG-005 and treponema in rhesus macaques infected with ABD clusters increased, and was positively correlated with the expression of interleukin, integrin and antiviral genes, while the abundance of microorganisms in rhesus macaques infected with PO cluster did not increase;(4) This study contributes to a deeper understanding of the role of gastrointestinal microbiota in SARS-CoV-2 infection and provides important information for the precise prevention, control, and treatment of COVID-19.
【Original Information】
Gastrointestinal microbiota and metabolites possibly contribute to distinct pathogenicity of SARS-CoV-2 proto or its variants in rhesus monkeys
2024-04-02 , Yogurt: 10.1080/19490976.2024.2334970
Two types of intestinal bacteria may help prevent COVID infection
Gut Microbes——[12.2]
(1) In this study, two gut microbes, Oribacterium sp. GMB0313 and Ruminococcus sp. GMB0270, were found to provide complete protection against SARS-CoV-2 by activating CD8+ T cell immune responses; Transplantation of fecal bacteria from individuals who were not infected or vaccinated against COVID-19 into a lethal COVID-19 hamster model showed that FMT from COVI-19D-resistant donors resulted in significant phenotypic changes in the susceptibility of hamsters to COVID-19;(3) metagenomic analysis revealed significant differences in the gut microbial composition of hamsters, and both bacteria were found to be associated with COVID-19 resistance;(4) two bacteria were given orally to hamsters by activating CD8+ T cell-mediated immunity, which provides complete protection against SARS-CoV-2 infection, and hamsters have achieved protection comparable to or even better than current mRNA vaccines;(5) Studies have shown that this has the potential for gut microbiome development as a host-oriented universal vaccine against all β coronaviruses.
【Original Information】
The gut microbe pair of Oribacterium sp. GMB0313 and Ruminococcus sp. GMB0270 confers complete protection against SARS-CoV-2 infection by activating CD8+ T cell-mediated immunity
2024-04-18 , Doi: 10.1080/19490976.2024.2342497
COVID has long-term gastrointestinal and psychological effects
Clinical Gastroenterology and Hepatology——[12.6]
(1) This article examines the long-term effects of COVID-19 on the gastrointestinal tract and finds that gut-brain interaction disorders (DGBIs) and persistent gastrointestinal symptoms have a high prevalence in hospitalized patients with COVID-19, and that persistent gastrointestinal manifestations correlate with the severity of gastrointestinal symptoms during hospitalization and the degree of psychological trauma associated with the experience of the disease;(2) 73 of the 116 patients were found to meet one or more Rome-based conditions at 12-18 months follow-up (3) 42.1% of patients who experienced COVID-related gastrointestinal symptoms (abdominal pain, nausea, vomiting, or diarrhea) during hospitalization retained at least one of these symptoms at follow-up, and 89.8% retained any COVID-related symptoms (gastrointestinal or non-gastrointestinal) during the initial onset of COVID-19; The number of severe gastrointestinal symptoms and the development of DGBIs at follow-up correlated with the severity of gastrointestinal symptoms;(5) PTSD associated with COVID-19 disease experience was found in 41.4% of respondents, and these individuals had higher prevalence of DGBIs and severity of gastrointestinal symptoms;(6) Psychological trauma scores were the strongest predictors of gastrointestinal symptom severity at follow-up.
【Original Information】
Prolonged gastrointestinal manifestations after recovery from COVID-19
2023-11-21 , Yogurt: 10.1016/J.CG.2023.11.009
Psychological interventions can improve the gut microbiota and inflammatory status in patients with Crohn's disease
Gut Microbes——[12.2]
(1) A three-month cognitive-behavioral and mindfulness-based daily exercise intervention was conducted to evaluate its effect on improving the health and inflammatory status of CD patients, as well as its effect on the gut microbiota;(2) Twenty-four CD patients and 25 healthy controls were included, and significant changes were found in the gut microbiota of CD patients after a three-month mindfulness daily exercise intervention, especially in the abundance of microbidia, families, and genera;(3) Baseline bacterial abundance was significantly correlated with psychological stress markers and IF n, suggesting that mindfulness-based daily exercise intervention may affect mental performance and systemic inflammation by regulating gut microbiota;(4) There was no significant change in α and β diversity between the two study groups, but there was a trend in β diversity.
【Original Information】
Cognitive behavioral and mindfulness with daily exercise intervention is associated with changes in intestinal microbial taxa and systemic inflammation in patients with Crohn's disease
2024-04-09 , Yogurt: 10.1080/19490976.2024.2337269
A gluten-free diet induces rapid changes in the phenotype and properties of gluten-specific T cells in celiac disease
Gastroenterology——[29.4]
(1) this study revealed the rapid effect of a gluten-free diet on the phenotype and survival characteristics of specific T cells in the blood and gut of patients with celiac disease;(2) the number of gluten-specific CD4+ T cells in the blood peaked during the first 14 days of the gluten-free diet, showing both Bcl-2 upregulation and Ki-67 downregulation, followed by a decrease in frequency over 10 weeks;(3) within three days of the start of the gluten-free diet, CD38, ICOS, Decreased expression of HLA-DR and Ki-67 in gluten-specific cells, (4) persistent expression of PD-1, CD39, and OX40 even after 12 months, and (5) significant decrease in IgA-TG2 over a four-week period provide an opportunity for clinical trials to develop non-dietary treatments for patients with newly diagnosed celiac disease.
【Original Information】
Gluten-free diet induces rapid changes in phenotype and survival properties of gluten-specific T cells in celiac disease
2024-03-27 , doi: 10.1053/j.gastro.2024.03.027
Nature: UC polygenic risk score predicts immunotherapy-associated colitis
Nature Communications——[16.6]
(1) Testing of the Polygenic Risk Score (PRSUC) in a cohort of 1316 patients with non-small cell lung cancer and 873 pan-cancer patients treated with immune checkpoint inhibitors (ICIs) found that PRSUC was significantly associated with all grades of colitis (IMC) and severe IMC; (2) PRSUC predicted a higher risk of severe IMC in patients treated with combination ICIs (ORmeta=2.20);(3) The polygenic risk score for Crohn's disease (PRSCD) is not associated with IMC;(4) This study suggests that PRSUC can identify the risk of IMC in patients undergoing ICI and may be helpful in monitoring patients and improving patient outcomes.
【Original Information】
Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis
2024-03-26, doi: 10.1038/s41467-023-44512-4
Domestic team: Intestinal microbiota-derived acetate may alleviate neuroinflammation and lower blood pressure
Journal of Neuroinflammation——[9.3]
(1) The team of Yanming Tian and Fang Yuan from Hebei Medical University found that the intestinal microbiota-derived acetate can reduce the neuroinflammation in the ventrolateral region (RVLM) of the medullary cephale (RVLM) of spontaneously hypertensive rats (SHRs), thereby exerting antihypertensive effects;(2) The serum acetate level of SHRs is lower than that of normal blood pressure rats;(3) Acetate supplementation can significantly reduce the arterial blood pressure and inhibit sympathetic nerve activity of SHRs;(4) Acetate supplementation can also inhibit RVLM neuroinflammation in SHRs, (5) This study revealed the relationship between gut microbiota metabolites and hypertension, and provided a new strategy for the treatment of hypertension.
【Original Information】
Microbiota-derived acetate attenuates neuroinflammation in rostral ventrolateral medulla of spontaneously hypertensive rats
2024-04-18, doi: 10.1186/s12974-024-03061-3
Comprehensive analysis of metabolomic, microbiome, and transcriptome data in a horse gut injury model
Microbiome——[15.5]
(1) Through comprehensive analysis of intestinal metabolome, microbiome and exfoliated cell transcriptome data, the mechanism of host-microbial interaction in the equine intestinal inflammation model induced by nonsteroidal anti-inflammatory drugs (NSAIDs) was revealed;(2) 20 horses were randomly divided into control group and NSAID group, and the NSAID group was given oral isobutyl phenylbutyrate for 9 consecutive days, and fecal samples were collected to analyze the changes in microbiome, metabolome and transcriptome of host exfoliated cells;(3) NSAID treatment caused microbiome, Significant changes in the metabolome and transcriptome, especially in specific bacterial genera, are associated with the expression of multiple genes and metabolites that are associated with oxidative stress;(4) changes in the microbiome and metabolites trigger endoplasmic reticulum stress and unfolded protein responses in the intestinal mucosa;(5) this study suggests that oxidative stress and subsequent cell signaling responses play an important role in a large animal model of gastroenteritis.
【Original Information】
Integrated analysis of gut metabolome, microbiome, and exfoliome data in an equine model of intestinal injury
2024-04-15, doi: 10.1186/s40168-024-01785-1
Paikin Biotech initiated the Phase 3 clinical trial of recombinant teduglutide for the treatment of SBS
(1) On April 19, Paikin Biotech announced that the phase 3 clinical trial of its recombinant tidoglutide for injection (PJ009) has been registered for the treatment of short bowel syndrome (SBS;(2) PJ009 is the first specific drug for SBS in China and has entered the phase 3 clinical stage;(3) Although Takeda's original drug teduglutide has been approved in China, it is expensive, with a three-month medical cost of nearly 400,000 yuan;(4) PJ009 is a glucagon-like peptide-2 similar peptide with low production cost, High product quality and easy industrialization and amplification.
【Original Information】
The first imitation in China, our recombinant didolitide for injection started phase III clinical trial
2024-04-19 , Paijin Biotech
GenFleet Pharmaceutical's colorectal cancer KRAS inhibitor was approved for Phase 3 clinical trial in the United States
(1) On April 19, GenFleet Pharma announced that it has received FDA approval for GFH925, its in-house developed KRAS G12C inhibitor, to conduct a Phase 3 clinical trial; (2) the trial will enroll patients with refractory, metastatic colorectal cancer who have failed two or more prior lines of systemic therapy or who are intolerant to the last treatment; (3) the study is designed to compare the efficacy, safety and tolerability of GFH925 monotherapy with standard therapy;(4) Inhibition of KRAS protein by GFH925 can further inhibit downstream signaling pathways, induce apoptosis and cell cycle arrest of tumor cells, and achieve anti-tumor effects.
【Original Information】
GenFleet Pharmaceutical's KRAS inhibitor was approved for Phase 3 clinical trial in the U.S. for the treatment of colorectal cancer
2024-04-19 , Pharma Guanlan
Bruker intends to acquire NanoString for $393 million in cash
(1) On April 17, NanoString Technologies announced that it would sell to Bruker for US$393 million (about 2.847 billion yuan), and the transaction is expected to be completed in early May this year;(2) NanoString Technologies, founded in 2003, is a space biomics company specializing in providing life science tools for translational research and molecular diagnostics;(3) Since its inception, the company has launched a number of products, including the nCounter analysis system, the GeoMx digital spatial analyzer, the CosMx spatial molecular imager, and the AtoMx spatial informatics platform.
【Original Information】
NanoString Technologies to Be Acquired by Bruker Corporation
2024-04-17 , Nanotsring
Yili Global Maternal and Child Nutrition Research Center was established in Europe
(1) On April 18, Yili announced the upgrade of Yili European Innovation Center (YICE) and the official establishment of Yili Global Maternal and Child Nutrition Research Center (YMINI Global;(2) Yili European Innovation Center shared the top ten scientific research achievements of the past ten years, and (3) Yili Global Maternal and Child Nutrition Research Center and Nature magazine jointly released the "Global Breast Milk Research White Paper".
【Original Information】
Yili Global Maternal and Child Nutrition Research Center was established in Europe
2024-04-22 , Foodaily
"Jinyu Medical" and "Kangrun Biotech" have cooperated to develop an intelligent immunofluorescence detection platform
(1) On April 10, Jinyu Medical and Kangrun Biotech signed a strategic cooperation agreement to jointly develop an intelligent immunofluorescence detection platform;(2) The two parties will jointly develop autoantibody immunofluorescence AI interpretation software to promote the clinical application of immunofluorescence detection technology;(3) The cooperation aims to build an industrial closed loop of AI + medical device manufacturing and improve the efficiency of diagnosis and treatment;(4) With 30 years of medical examination experience, Jinyu Medical has successful cases in the field of medical examination + AI, while Kangrun Biotech focuses on immunodiagnostic technology;(5) This cooperation is expected to improve the accuracy and efficiency of the detection of autoimmune diseases and infectious diseases, and promote the intelligent upgrading of immunofluorescence detection technology in China.
【Original Information】
Jinyu Medical has joined hands with Kangrun Biotech to develop an intelligent immunofluorescence detection platform
2024-04-22 , Jinyu Medical
感谢本期日报的审核者:mildbreeze,章台柳,圆圈儿,RZN,九卿臣,Richard,617
Click here to read the daily reports for the past 10 days:
0422 | Expert voices: Two articles in Cell focus on microbiota and cancer treatment
0421 | Food as Medicine: 10 articles focusing on dietary interventions in disease
0420 | Science揭秘：肠道中的噬菌体-病菌"军备竞赛"
0419 | Cheng Gong/Zhu Yibin/Wang Jinglin et al. Science breakthrough: clever use of symbiotic bacteria to block the transmission of mosquito-borne viruses
0418 | 聚焦特殊人群：母婴肠道菌群与健康
0417 | High-score Nature sub-journal: Bringing together the power of global players to help intestinal microbiome research
0416 | Multi-article focus: To protect the gut, no one can do without immune cells and microflora
0415 | Cell Blockbuster Review: Systematic Analysis of Cancer Complexity, the Role of Microbiota Should Not Be Underestimated
0414 | A review of the high-scoring Cell sub-journal, an article about fermented foods
0413 | 3 major articles in the sub-journal to analyze the current situation and future of microbiome therapy